- Report
- October 2026
- 382 Pages
Global
From €5399EUR$5,850USD£4,520GBP
- Report
- October 2026
- 383 Pages
Global
From €5399EUR$5,850USD£4,520GBP
- Report
- October 2026
- 575 Pages
Global
From €5399EUR$5,850USD£4,520GBP
- Report
- October 2026
- 375 Pages
Global
From €5399EUR$5,850USD£4,520GBP
- Report
- August 2026
- 115 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- August 2026
- 110 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- July 2026
- 135 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- June 2026
- 180 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- June 2026
- 140 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- April 2026
- 180 Pages
Global
From €4384EUR$4,750USD£3,670GBP
- Report
- July 2026
- 150 Pages
Global
From €3461EUR$3,750USD£2,898GBP
- Report
- May 2026
- 149 Pages
Global
From €3645EUR$3,950USD£3,052GBP
- Report
- August 2026
- 176 Pages
Global
From €3645EUR$3,950USD£3,052GBP
- Report
- April 2026
- 160 Pages
Global
From €3064EUR$3,320USD£2,565GBP
€3830EUR$4,150USD£3,207GBP
- Report
- November 2025
- 150 Pages
Global
From €4476EUR$4,850USD£3,748GBP
- Report
- July 2026
- 75 Pages
Asia Pacific
From €4384EUR$4,750USD£3,670GBP
- Report
- January 2025
- 152 Pages
Global
From €2077EUR$2,250USD£1,739GBP
- Report
- August 2025
- 200 Pages
United States
From €2298EUR$2,490USD£1,924GBP
- Report
- February 2025
- 100 Pages
Global
From €5491EUR$5,950USD£4,598GBP
- Report
- December 2022
- 130 Pages
Global
From €5491EUR$5,950USD£4,598GBP

Circulating Tumor DNA (ctDNA) is a type of genetic material found in the bloodstream of cancer patients. It is a valuable tool for cancer diagnosis, prognosis, and treatment. ctDNA can be used to detect the presence of cancer, identify the type of cancer, and monitor the progression of the disease. It can also be used to detect mutations in cancer cells, which can help guide treatment decisions.
ctDNA is a rapidly growing field in genomics, with many companies developing technologies to detect and analyze ctDNA. These companies are developing technologies such as next-generation sequencing, digital PCR, and microfluidics to detect and analyze ctDNA. Companies are also developing technologies to detect and analyze ctDNA in real-time, allowing for more accurate and timely diagnosis and treatment.
Some companies in the ctDNA market include Illumina, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, and Guardant Health. Show Less Read more